Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 4
1973 1
1974 4
1975 8
1976 9
1977 4
1978 5
1979 4
1980 3
1982 5
1983 4
1984 3
1985 3
1986 1
1987 2
1988 2
1989 1
1990 2
1991 3
1992 2
1993 1
1994 3
1996 2
1998 3
1999 1
2000 2
2001 1
2003 4
2004 2
2005 5
2006 1
2007 5
2008 4
2009 1
2010 2
2011 4
2012 1
2013 2
2014 3
2015 9
2016 1
2017 2
2018 5
2019 6
2020 6
2021 5
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Koi L, Bitto V, Weise C, Möbius L, Linge A, Löck S, Yaromina A, Besso MJ, Valentini C, Pfeifer M, Overgaard J, Zips D, Kurth I, Krause M, Baumann M. Koi L, et al. J Transl Med. 2023 Aug 26;21(1):576. doi: 10.1186/s12967-023-04439-2. J Transl Med. 2023. PMID: 37633930 Free PMC article.
Here, we investigated the impact of nimorazole combined with RCTx in HNSCC xenografts and explored molecular biomarkers for its targeted use. ...Effect of RCTx with or without addition of nimorazole was quantified as permanent local control after irradiation. ...
Here, we investigated the impact of nimorazole combined with RCTx in HNSCC xenografts and explored molecular biomarkers for its targe …
Bound Electron Enhanced Radiosensitisation of Nimorazole upon Charge Transfer.
Kumar S, Ben Chouikha I, Kerkeni B, García G, Limão-Vieira P. Kumar S, et al. Molecules. 2022 Jun 28;27(13):4134. doi: 10.3390/molecules27134134. Molecules. 2022. PMID: 35807379 Free PMC article.
This novel work reports nimorazole (NIMO) radiosensitizer reduction upon electron transfer in collisions with neutral potassium (K) atoms in the lab frame energy range of 10-400 eV. ...Additional information on the electronic state spectroscopy of nimorazole was obt …
This novel work reports nimorazole (NIMO) radiosensitizer reduction upon electron transfer in collisions with neutral potassium (K) a …
(15) N NMR Hyperpolarization of Radiosensitizing Antibiotic Nimorazole by Reversible Parahydrogen Exchange in Microtesla Magnetic Fields.
Salnikov OG, Chukanov NV, Svyatova A, Trofimov IA, Kabir MSH, Gelovani JG, Kovtunov KV, Koptyug IV, Chekmenev EY. Salnikov OG, et al. Angew Chem Int Ed Engl. 2021 Feb 1;60(5):2406-2413. doi: 10.1002/anie.202011698. Epub 2020 Dec 1. Angew Chem Int Ed Engl. 2021. PMID: 33063407 Free PMC article.
Nimorazole belongs to the imidazole-based family of antibiotics to fight against anaerobic bacteria. Moreover, nimorazole is now in Phase 3 clinical trial in Europe for potential use as a hypoxia radiosensitizer for treatment of head and neck cancers. ...
Nimorazole belongs to the imidazole-based family of antibiotics to fight against anaerobic bacteria. Moreover, nimorazole is n …
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
Thomson DJ, Slevin NJ, Baines H, Betts G, Bolton S, Evans M, Garcez K, Irlam J, Lee L, Melillo N, Mistry H, More E, Nutting C, Price JM, Schipani S, Sen M, Yang H, West CM; NIMRAD Trial Group. Thomson DJ, et al. Int J Radiat Oncol Biol Phys. 2023 Dec 9:S0360-3016(23)08184-1. doi: 10.1016/j.ijrobp.2023.11.055. Online ahead of print. Int J Radiat Oncol Biol Phys. 2023. PMID: 38072326 Free article.
Similarly, nimorazole + IMRT did not improve FFLRP or overall survival in the whole population. In total (N = 338), 73% of patients allocated nimorazole adhered to the drug for 50% of IMRT fractions. Nimorazole + IMRT caused more acute nausea compared with pl …
Similarly, nimorazole + IMRT did not improve FFLRP or overall survival in the whole population. In total (N = 338), 73% of patients a …
Low-energy electrons transform the nimorazole molecule into a radiosensitiser.
Meißner R, Kočišek J, Feketeová L, Fedor J, Fárník M, Limão-Vieira P, Illenberger E, Denifl S. Meißner R, et al. Nat Commun. 2019 Jun 3;10(1):2388. doi: 10.1038/s41467-019-10340-8. Nat Commun. 2019. PMID: 31160602 Free PMC article.
This supports the hypothesis that nimorazole is selectively cytotoxic to tumour cells due to reduction of the molecule as prerequisite for accumulation in the cell. ...Our results show that LEEs may strongly contribute to the radiosensitising effect of nimorazole vi …
This supports the hypothesis that nimorazole is selectively cytotoxic to tumour cells due to reduction of the molecule as prerequisit …
Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole.
Musiał-Kulik M, Włodarczyk J, Stojko M, Karpeta-Jarząbek P, Pastusiak M, Janeczek H, Kasperczyk J. Musiał-Kulik M, et al. Eur J Pharm Biopharm. 2021 Apr;161:29-36. doi: 10.1016/j.ejpb.2021.02.001. Epub 2021 Feb 7. Eur J Pharm Biopharm. 2021. PMID: 33567313
To find a potential option of glioblastoma treatment the bioresorbable, layer nonwoven mats for controlled temozolomide and nimorazole release were obtained by classical and coaxial electrospinning. ...Results form the basis for further investigation since both studied pol …
To find a potential option of glioblastoma treatment the bioresorbable, layer nonwoven mats for controlled temozolomide and nimorazole …
Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
Cottrill CP, Bishop K, Walton MI, Henk JM. Cottrill CP, et al. Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):807-10. doi: 10.1016/s0360-3016(98)00309-5. Int J Radiat Oncol Biol Phys. 1998. PMID: 9845101 Clinical Trial.
CONCLUSIONS: Comparison with a historical group of patients, treated with the CHART regimen alone and matched for irradiation volume and technique, showed that nimorazole did not increase the severity of acute normal tissue radiation effects. Encouraging tumor responses ha …
CONCLUSIONS: Comparison with a historical group of patients, treated with the CHART regimen alone and matched for irradiation volume and tec …
Treatment of head and neck cancer with CHART and nimorazole: phase II study.
Henk JM, Bishop K, Shepherd SF. Henk JM, et al. Radiother Oncol. 2003 Jan;66(1):65-70. doi: 10.1016/s0167-8140(02)00284-0. Radiother Oncol. 2003. PMID: 12559522 Clinical Trial.
Normal tissue effects were the same as those previously seen with CHART, except for a possible slight increase in acute skin reaction. Nimorazole toxicity was somewhat greater than with once daily administration in previous studies. ...CONCLUSIONS: Local control rates are …
Normal tissue effects were the same as those previously seen with CHART, except for a possible slight increase in acute skin reaction. Ni …
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Sugie C, Shibamoto Y, Ito M, Ogino H, Suzuki H, Uto Y, Nagasawa H, Hori H. Sugie C, et al. J Radiat Res. 2005 Dec;46(4):453-9. doi: 10.1269/jrr.46.453. J Radiat Res. 2005. PMID: 16394636 Free article.
Under hypoxic conditions, the sensitizer enhancement ratio (SER) determined at 1% cell survival level for sanazole, nimorazole and KU-2285 was 1.55, 1.45 and 1.95, respectively, at 1 mM, and 1.40, 1.40 and 1.75, respectively, at 0.5 mM. In vivo, all three compounds had sig …
Under hypoxic conditions, the sensitizer enhancement ratio (SER) determined at 1% cell survival level for sanazole, nimorazole and KU …
151 results

Searches related to "nimorazole"